PRFX is trading at $1.51 (5.6% down) in a pre-market pullback following a sharp rally triggered by positive preclinical results for its lead pain candidate, PRF-110.
- The stock surged 13.48% on June 25, 2026, after the company reported expanded positive data for its pain management treatment.
- Current price action appears to be a typical technical retracement following the news-based rally rather than a reaction to new negative company-specific developments.